AWM Investment Company Inc. Has $1.05 Million Stake in OptimizeRx Co. (NASDAQ:OPRX)

AWM Investment Company Inc. decreased its stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 79.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 215,421 shares of the company's stock after selling 856,411 shares during the quarter. AWM Investment Company Inc. owned 1.17% of OptimizeRx worth $1,047,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Whetstone Capital Advisors LLC bought a new position in OptimizeRx in the fourth quarter valued at approximately $6,563,000. Royce & Associates LP bought a new stake in OptimizeRx during the fourth quarter worth $5,198,000. Kennedy Capital Management LLC grew its holdings in OptimizeRx by 57.8% during the fourth quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock worth $2,887,000 after purchasing an additional 217,676 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of OptimizeRx by 9.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company's stock worth $2,159,000 after acquiring an additional 39,740 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of OptimizeRx by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 400,621 shares of the company's stock valued at $1,948,000 after purchasing an additional 4,821 shares during the period. Institutional investors and hedge funds own 76.47% of the company's stock.

OptimizeRx Trading Down 2.0%

OPRX opened at $11.95 on Wednesday. The company has a market cap of $221.02 million, a P/E ratio of -8.98 and a beta of 1.28. The company has a fifty day moving average price of $8.95 and a two-hundred day moving average price of $6.57. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx Co. has a 1-year low of $3.78 and a 1-year high of $13.19.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. The business had revenue of $21.93 million during the quarter, compared to analyst estimates of $18.69 million. Analysts predict that OptimizeRx Co. will post -0.33 EPS for the current fiscal year.

Analysts Set New Price Targets

OPRX has been the topic of several recent research reports. JMP Securities increased their price objective on OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a research report on Tuesday, May 13th. B. Riley reissued a "buy" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Roth Capital reaffirmed a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Stifel Nicolaus raised their price objective on shares of OptimizeRx from $8.00 to $12.50 and gave the company a "buy" rating in a report on Tuesday, May 13th. Finally, Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.38.

Insider Activity at OptimizeRx

In other news, Director James Paul Lang purchased 321,408 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the acquisition, the director now owns 389,452 shares in the company, valued at $2,959,835.20. This trade represents a 472.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.60% of the stock is owned by insiders.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

Want to see what other hedge funds are holding OPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Co. (NASDAQ:OPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.